News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI Yael L. Maxwell November 13, 2017
News Conference News TCT 2017 RECAP: In the Cath Lab, a Lead-free Pad Placed on the Patient Cuts Operator Radiation Exposure Todd Neale November 01, 2017
News Conference News VIVA 2017 Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD L.A. McKeown September 18, 2017
News Conference News VIVA 2017 DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease L.A. McKeown September 13, 2017
News Conference News ESC 2017 Acute MI Mortality Has Dropped to Very Low Levels in France Todd Neale September 08, 2017
News Conference News ESC 2017 VIVA: Could Population-Wide Screening Trial for AAA, PAD, and Hypertension Save Lives at Low Cost? Shelley Wood August 28, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News TVT 2017 Mitral Valve Repair Technologies Inch Forward, but Question of Combination Therapy Looms Shelley Wood June 15, 2017
News Conference News ISET 2017 Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs? Caitlin E. Cox February 17, 2017
News Conference News ISET 2017 Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360 Caitlin E. Cox February 07, 2017
News Conference News ISET 2017 Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not? Caitlin E. Cox February 06, 2017